Peginterferon alpha 2a Ribavirin Eldecalcitol

3 trials

Sponsors

Department of Hepatology, Osaka City University, Department of Hepatology, Osaka City University Graduate School of Medicine

Conditions

Chronic hepatitis C with osteoporosisHepatitis C virus-related compensated cirrhosis with osteoporosis

Unknown Phase

The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosis

Active, not recruitingJPRN-UMIN000007070

Department of Hepatology, Osaka City University Graduate School of MedicineChronic hepatitis C with osteoporosis

Start: 2011-09-01Target: 50Updated: 2026-06-29

The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for hepatitis C virus-related compensated cirrhosis with osteoporosis

Active, not recruitingJPRN-UMIN000006283

Department of Hepatology, Osaka City UniversityHepatitis C virus-related compensated cirrhosis with osteoporosis

Start: 2014-03-31Target: 50Updated: 2026-06-29

The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosis

Active, not recruitingJPRN-UMIN000006285

Department of Hepatology, Osaka City UniversityChronic hepatitis C with osteoporosis

Start: 2011-07-01Target: 50Updated: 2026-06-29